Clinical trials
Lung Cancer, Small Cell clinical trials
Below are recruiting lung cancer, small cell clinical trials, each written for real people, not researchers. We’re tracking 1,490 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06954246RecruitingPhase 3
New drug vs. doctor’s choice for relapsed small cell lung cancer
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
ShanghaiAges 18 years+ - NCT06956001RecruitingPhase 3
Testing firmanertinib vs chemo for first-line lung cancer with specific EGFR mutations
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06953843RecruitingPhase 2
Radiation and Immunotherapy for Advanced Lung Cancer
This trial tests a combination of radiation and immunotherapy to see if it can make the immune system attack cancer throughout the body in people with advanced lung cancer that has spread to many places. It's for those whose cancer does not have certain genetic changes and who have not had uncontrolled brain metastases.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06957314Recruiting
Hospital-at-home for people receiving Tarlatamab
This study tests giving hospital-type care at home for people with extensive-stage small cell lung cancer who are receiving the drug Tarlatamab. It aims to see if patients can safely receive their treatment at home instead of in the hospital.
Basking Ridge, New JerseyAges 18 years+ - NCT04952480RecruitingPhase 2
Adaptive chest radiation for newly diagnosed small cell lung cancer
This study tests a customized (“adaptive”) way to give radiation to the chest for newly diagnosed small cell lung cancer. It aims to improve how well treatment targets the tumor while safely adjusting to tumor changes during therapy.
Edmonton, AlbertaAges 18 years+ - NCT05765877RecruitingPhase 2
Study drug before surgery for ALK or ROS1 lung cancer
This Phase 2 trial tests WX-0593 given before surgery for certain types of lung cancer that have ALK or ROS1 gene changes. The goal is to shrink or control the cancer ahead of the operation and see how well the treatment works and is tolerated.
Jinan, ShandongAges 18 years+ - NCT06418412Recruiting
Pan-Asian study for EGFR exon 20 insertion lung cancer
This trial is building a large database of lung cancer patients from Asia who have a specific EGFR mutation (exon 20 insertion). Your medical records and treatment information will be collected to help doctors learn more about this type of cancer and improve care.
SingaporeAges 21–99 - NCT05613452RecruitingPhase 2
Carbon ion radiation for peripheral lung cancer you can’t operate on
This trial tests whether carbon ion radiation (high-energy targeted radiation) can control peripheral non-small cell lung cancer in people who are medically unable to have surgery. It may help shrink or stop tumor growth while limiting harm to nearby organs.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06311981RecruitingPhase 2
Carbon ion radiation for elderly lung cancer patients
This trial tests carbon ion radiotherapy for adults 75 and older with locally advanced non-small cell lung cancer who cannot have surgery. The goal is to see if this precise type of radiation can treat the cancer effectively with fewer side effects.
Shanghai, Shanghai MunicipalityAges 75 years+ - NCT06947694RecruitingPhase 2
Testing radioimmunotherapy combinations for lung cancer with metastases
This trial explores whether combining radiation therapy with immunotherapy can trigger an immune response that shrinks tumors throughout the body (abscopal effect) in people with non-small cell lung cancer that has spread to 3 to 6 other sites. It tests different patterns of these treatments to see which works best.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06951464RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
Chengdu, SichuanAges 18–75 - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75 - NCT06943235RecruitingPhase 2
Probiotics, radiation, chemo, and immunotherapy for limited-stage small cell lung cancer
This trial tests if adding probiotics (good bacteria) to standard chemoradiation and an immunotherapy drug (adebrelimab) can help treat limited-stage small cell lung cancer. It may improve how well the treatment works and reduce side effects.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06946927RecruitingPhase 1
Study of JMKX001899 with other drugs for advanced KRAS G12C lung cancer
This trial tests a new targeted therapy, JMKX001899, combined with other treatments for advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It aims to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT06934343Recruiting
Personalized therapy for advanced lung cancer using data
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
Salt Lake City, UtahAges Any age - NCT06205927RecruitingPhase 2
Carbon Ion Boost for Advanced Lung Cancer
This trial tests a new way to give radiation therapy (carbon ion boost) to people with advanced, inoperable lung cancer. The goal is to see if targeting the most aggressive parts of the tumor with a higher dose can improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06775678RecruitingPhase 2
Spatial fragmentation plus low-dose radiation for resistant lung cancer
This study tests whether combining a special type of radiation (spatial fragmentation) with low-dose radiation can help people whose lung cancer stopped responding to immunotherapy and chemotherapy. If you are eligible, you may receive a new treatment approach to try to shrink the tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06931717RecruitingPhase 3
Immunotherapy after lung cancer surgery for those not getting chemo
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
ViennaAges 18 years+ - NCT06923618Recruiting
Lung Cancer and Aging in Older Adults
This trial looks at aging-related changes in older adults (70+) with early-stage lung cancer who are planning to have surgery. The goal is to better understand how these changes might affect recovery and outcomes, which could help improve care for future patients.
Créteil, Île-de-France RegionAges 70 years+ - NCT06926140Recruiting
Acupuncture with immunotherapy for advanced lung cancer
This trial tests if adding acupuncture to standard immunotherapy and chemotherapy helps people with advanced lung cancer. It is for those who have not had treatment before and whose tumors have low PD-L1 levels.
Hefei, AnhuiAges 18–75 - NCT06930794RecruitingPhase 3
Study of Vebreltinib Plus Chemo for MET-Positive Lung Cancer
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06931626RecruitingPhase 1
Study of NMS-03305293 for relapsed small cell lung cancer
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Peoria, IllinoisAges 18 years+ - NCT06928389RecruitingPhase 3
Ivonescimab plus docetaxel for advanced lung cancer
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Lung Cancer, Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer, small cell?
- Yes. Clin2 currently lists 1,490 recruiting lung cancer, small cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer, small cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer, small cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.